Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)
- 5 July 2022
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 57 (8) , 587-597
Abstract
Background We developed a nationwide database that stores data of patients with primary liver cancer (PLC) and decompensated cirrhosis (DC) on an admission basis. Methods A database was constructed using the National Clinical Database, a nationwide registry platform for various diseases in Japan. Mutual data exchange was possible with the Nationwide Follow-up Survey of Primary Liver Cancer in Japan by the Liver Cancer Study Group of Japan. The stored data on the admission of patients with PLC, DC, or both, included treatment details as well as patient characteristics. Results A total of 37,705 admissions (29,489 PLC, 10,077 DC, and 1862 for both) in 21,376 patients from 224 hospitals were analyzed. The proportions of patients with hepatitis B, hepatitis C, and non-viral etiology were 11.9%, 36.2%, and 42.6%, respectively, in PLC, and 7.5%, 23.8%, and 55.0%, respectively, in DC. The mean ages (± standard deviation) on admission with PLC and DC were 73 ± 10 and 68 ± 13 years, respectively. The Barcelona Clinic Liver Cancer (BCLC) stage for PLC was 0, A, B, C, and D in 22.0%, 17.1%, 29.6%, 15.1%, and 5.1%, respectively. Treatment modalities for PLC were resection, ablation, transarterial chemoembolization, and systemic therapy in 18.4%, 22.8%, 33.7%, and 11.4%, respectively. A vasopressin receptor V2 antagonist was used in 38.2% in addition to conventionally used loop diuretics and aldosterone antagonists for DC. Conclusions The distribution of treatment options for PLC on admission differed from that of the initial treatment. Newly introduced drugs are widely used in patients with DC.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (H30-Kansei-Shitei-003)
This publication has 40 references indexed in Scilit:
- Tolvaptan for the treatment of liver cirrhosis oedemaExpert Review of Gastroenterology & Hepatology, 2014
- Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular CarcinomaAnnals of Surgery, 2014
- Overview of the Surveillance, Epidemiology, and End Results Database: Evolution, Data Variables, and Quality AssuranceCurrent Problems in Cancer, 2012
- Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic reviewWorld Journal of Surgical Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Liver cirrhosisThe Lancet, 2008
- Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 PatientsGastroenterology, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Results of Surgical and Nonsurgical Treatment for Small–Sized Hepatocellular Carcinomas: A Retrospective and Nationwide Survey in JapanHepatology, 2000
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973